Ke Zhao1, Jing Cheng1, Baojun Chen1, Qi Liu1, Di Xu1, Yongjian Zhang1. 1. Department of Thoracic Surgery, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430014, China.
Abstract
BACKGROUND: To evaluate the association of plasma miR-34a/b/c expressions with the clinicopathological properties and the prognosis in non-small cell lung cancer (NSCLC) patients. METHODS: A total of 196 NSCLC patients were recruited in the study. Plasma sample and tumor tissue sample were collected. Total RNA was extracted from plasma and tissue samples, and microR-34a/b/c expression was evaluated by real-time polymerase chain reaction (PCR). RESULTS: MiR-34a and miR-34c in plasma were positively associated with that in tumor tissue (P<0.001 and P=0.001, respectively). Plasma miR-34a expression was negatively correlated with lymph node metastasis (P=0.002), also tissue miR-34a expression was negatively associated with lymph node metastasis (P=0.018). Furthermore, plasma miR-34a high expression was correlated with prolonged disease-free survival (DFS) (P=0.011) and overall survival (OS) (P=0.011) compared to low expression, and plasma miR-34c high expression could predict longer DFS (P=0.038) than low expression, while no correlation of plasma miR-34b with DFS and OS was discovered. In terms of tissue sample, worse DFS was associated with miR-34a (P=0.002) and miR-34c (P=0.032) low expressions compared with high expressions, and miR-34a (P<0.001), as well as miR-34c (P=0.003) high expressions were associated with longer OS than low expressions. Plasma miR-34a was correlated with prolonged DFS and OS in univariate Cox model, while it could not independently predict DFS and OS of NSCLC patients in multivariate Cox model. CONCLUSIONS: In conclusion, circulating miR-34a and miR-34c might be served as novel prognostic biomarkers in NSCLC patients.
BACKGROUND: To evaluate the association of plasma miR-34a/b/c expressions with the clinicopathological properties and the prognosis in non-small cell lung cancer (NSCLC) patients. METHODS: A total of 196 NSCLC patients were recruited in the study. Plasma sample and tumor tissue sample were collected. Total RNA was extracted from plasma and tissue samples, and microR-34a/b/c expression was evaluated by real-time polymerase chain reaction (PCR). RESULTS: MiR-34a and miR-34c in plasma were positively associated with that in tumor tissue (P<0.001 and P=0.001, respectively). Plasma miR-34a expression was negatively correlated with lymph node metastasis (P=0.002), also tissue miR-34a expression was negatively associated with lymph node metastasis (P=0.018). Furthermore, plasma miR-34a high expression was correlated with prolonged disease-free survival (DFS) (P=0.011) and overall survival (OS) (P=0.011) compared to low expression, and plasma miR-34c high expression could predict longer DFS (P=0.038) than low expression, while no correlation of plasma miR-34b with DFS and OS was discovered. In terms of tissue sample, worse DFS was associated with miR-34a (P=0.002) and miR-34c (P=0.032) low expressions compared with high expressions, and miR-34a (P<0.001), as well as miR-34c (P=0.003) high expressions were associated with longer OS than low expressions. Plasma miR-34a was correlated with prolonged DFS and OS in univariate Cox model, while it could not independently predict DFS and OS of NSCLC patients in multivariate Cox model. CONCLUSIONS: In conclusion, circulating miR-34a and miR-34c might be served as novel prognostic biomarkers in NSCLC patients.
Authors: Romain Remark; Christian Becker; Jorge E Gomez; Diane Damotte; Marie-Caroline Dieu-Nosjean; Catherine Sautès-Fridman; Wolf-Herman Fridman; Charles A Powell; Nasser K Altorki; Miriam Merad; Sacha Gnjatic Journal: Am J Respir Crit Care Med Date: 2015-02-15 Impact factor: 21.405
Authors: Gang Zhao; Bo Wang; Yang Liu; Jun-Gang Zhang; Shi-Chang Deng; Qi Qin; Kui Tian; Xiang Li; Shuai Zhu; Yi Niu; Qiong Gong; Chun-You Wang Journal: Mol Cancer Ther Date: 2013-09-06 Impact factor: 6.261
Authors: Ji Hyung Hong; Kang San Roh; Sung-Suk Suh; Sukchan Lee; Sook Whan Sung; Jae Kil Park; Jae Ho Byun; Jin Hyoung Kang Journal: Tumour Biol Date: 2015-06-25
Authors: Jason D Arroyo; John R Chevillet; Evan M Kroh; Ingrid K Ruf; Colin C Pritchard; Donald F Gibson; Patrick S Mitchell; Christopher F Bennett; Era L Pogosova-Agadjanyan; Derek L Stirewalt; Jonathan F Tait; Muneesh Tewari Journal: Proc Natl Acad Sci U S A Date: 2011-03-07 Impact factor: 11.205
Authors: Soo J Park; Soham More; Ayesha Murtuza; Brian D Woodward; Hatim Husain Journal: Hematol Oncol Clin North Am Date: 2017-02 Impact factor: 3.722
Authors: Jaileene Pérez-Morales; Hong Lu; Wei Mu; Ilke Tunali; Tugce Kutuk; Steven A Eschrich; Yoganand Balagurunathan; Robert J Gillies; Matthew B Schabath Journal: Cancer Biomark Date: 2022 Impact factor: 3.828
Authors: Melissa L New; Collin M White; Polly McGonigle; Debbie G McArthur; Lori D Dwyer-Nield; Daniel T Merrick; Robert L Keith; Meredith A Tennis Journal: Cancer Prev Res (Phila) Date: 2018-07-25